Progress in the risk assessment of hydroxychloroquine in frail elderly people.
COVID‐19
QTc prolongation risk score
hydroxychloroquine
Journal
Aging medicine (Milton (N.S.W))
ISSN: 2475-0360
Titre abrégé: Aging Med (Milton)
Pays: Australia
ID NLM: 101741954
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
19
08
2020
revised:
24
11
2020
accepted:
24
11
2020
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
20
3
2021
Statut:
epublish
Résumé
Hydroxychloroquine (HCQ) is an antimalarial drug also known to have anti-inflammatory and antiviral effects. The antiviral action of HCQ has been a point of interest for many researchers because of its mechanism of action and the potential use it could have during the current COVID-19 pandemic. However, HCQ can cause QT interval prolongation. The current therapies used in COVID-19 are changing as the pandemic develops. The aim of this article is to promote a validated risk score for QT prolongation in multidimensional assessment of COVID-19 patients, especially in elderly and polypathological patients.
Identifiants
pubmed: 33738381
doi: 10.1002/agm2.12140
pii: AGM212140
pmc: PMC7954841
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
53-57Informations de copyright
© 2020 The Authors. Aging Medicine published by Beijing Hospital and John Wiley & Sons Australia, Ltd.
Déclaration de conflit d'intérêts
Nothing to disclose.
Références
Prog Cardiovasc Dis. 2020 May - Jun;63(3):390-391
pubmed: 32169400
Am Heart J. 2021 Feb;232:105-115
pubmed: 33121978
Drug Saf Case Rep. 2017 Dec;4(1):6
pubmed: 28258476
Am J Med. 1983 Aug;75(2):249-58
pubmed: 6881176
Int Urol Nephrol. 2018 Aug;50(8):1505-1510
pubmed: 29868939
Lancet. 2020 May 22;:
pubmed: 32450107
Circulation. 2010 Mar 2;121(8):1047-60
pubmed: 20142454
N Engl J Med. 2020 Aug 6;383(6):585-586
pubmed: 32492298
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
J Interferon Cytokine Res. 2015 Mar;35(3):143-56
pubmed: 25321315
Can Pharm J (Ott). 2016 May;149(3):139-52
pubmed: 27212965
Ann Intern Med. 2020 Aug 18;173(4):287-296
pubmed: 32459529
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
New Microbes New Infect. 2020 Apr 22;35:100684
pubmed: 32322397
Clin Toxicol (Phila). 2006;44(2):173-5
pubmed: 16615675
Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):479-87
pubmed: 23716032
Prog Cardiovasc Dis. 2001 Mar-Apr;43(5 Suppl 1):1-45
pubmed: 11269621
Lancet Infect Dis. 2007 Aug;7(8):549-58
pubmed: 17646028
N Engl J Med. 2020 Aug 6;383(6):517-525
pubmed: 32492293
Geriatr Gerontol Int. 2015 Jul;15(7):895-901
pubmed: 25243349
Cell Discov. 2020 Mar 18;6:16
pubmed: 32194981
Br Heart J. 1990 Jun;63(6):342-4
pubmed: 2375895
Br J Clin Pharmacol. 2013 Jul;76(1):48-57
pubmed: 23167578
Card Electrophysiol Rev. 2002 Sep;6(3):278-81
pubmed: 12114852
Age (Dordr). 2013 Aug;35(4):1433-44
pubmed: 22760858
Drug Saf. 2012 Jun 1;35(6):459-70
pubmed: 22612851
Med Mal Infect. 2020 Jun;50(4):384
pubmed: 32240719
J Am Coll Cardiol. 2010 Mar 2;55(9):934-47
pubmed: 20185054
Am Heart J. 2007 Jun;153(6):891-9
pubmed: 17540188
J Am Geriatr Soc. 2020 Dec;68(12):2746
pubmed: 32770838
N Engl J Med. 1998 Oct 1;339(14):960-5
pubmed: 9753711
Am Heart J. 1984 Mar;107(3):425-30
pubmed: 6695683
BMJ. 2009 Jan 08;338:a3083
pubmed: 19131384
Eur Heart J. 1990 Nov;11 Suppl G:29-38
pubmed: 1981552
Circulation. 1991 Sep;84(3):1136-44
pubmed: 1884444
Pediatr Cardiol. 1983 Apr-Jun;4(2):139-48
pubmed: 6348715
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041
pubmed: 32936252
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Clin Exp Dermatol. 2012 Jun;37(4):327-34
pubmed: 22582908
Lancet. 2020 May 22;:
pubmed: 32450109
Eur Heart J. 1998 Sep;19(9):1391-400
pubmed: 9792266
Nat Med. 2020 Jun;26(6):808-809
pubmed: 32488217
Inflammopharmacology. 2018 Oct;26(5):1141-1149
pubmed: 29948492